

SPECIFICATION AMENDMENTS

In the Specification:


The specification has been amended to include a sequence listing for the sequences found in the specification. A sequence listing paper copy has been submitted with this Amendment as additional sheets to the specification to be inserted before the claims. A computer readable form has also been submitted and it is the same as the paper copy that has been added. Additionally, the Specification has been amended according to the attached Specification replacement sheets.

Specifically,

- On page 9, line 19, following -- 5'-rCrUrUrArCrGrCrUrGrArGrUrArCrUrUrCrGrATT-3' -- please insert -- (SEQ ID NO: 1) --
- On page 9, line 24, following -- 5'-rUrCrGrArArGrUrArCrUrCrArGrCrGrUrArArGTT-3' -- please insert -- (SEQ ID NO: 2) --
- On page 10, line 1, following -- 5'-rGrCrGrArUrArArGrUrCrGrUrGrUrCrUrUrArCTT-3' -- please insert -- (SEQ ID NO: 3) --
- On page 10, line 5, following -- 5'-rGrUrArArGrArCrArCrGrArCrUrUrArUrCrGrCTT-3' -- please insert -- (SEQ ID NO: 4) --
- On page 14, line 26, following -- 5'-rArGrGrGrCrArArCrUrUrCrCrArGrArCrCrArUTT-3' -- please insert -- (SEQ ID NO: 5) --
- On page 14, line 31, following -- 5'-rArUrGrGrUrCrUrGrGrArArGrUrUrGrCrCrCrUTT-3' -- please insert -- (SEQ ID NO: 6) --
- On page 16, line 9, following -- 5'-rCrArCrUrCrArGrUrCrUrArArGrGrGrCrUTT-3' -- please insert -- (SEQ ID NO: 7) --
- On page 16, line 16, following -- 5'-rArGrCrCrUrArGrArCrUrGrArGrUrGTT-3' -- please insert -- (SEQ ID NO: 8) --

Applicants hereby submit a marked version of each Replacement Page. Please enter replacement pages 9, 10, 14, and 16. The sheets do not include new matter.

Respectfully submitted,



Mark K. Johnson Reg. No. 35,909
Mirus
505 South Rosa Road
Madison, WI 53719
608-238-4400

I hereby certify that this correspondence is being
facsimile transmitted to the USPTO 703.308.4242
addressed to: Assistant Commissioner for Patents,
Washington, DC 20231 on Aug. 1, 2003.



Kirk Ekena



RECEIVED
AUG 06 2003
TECH CENTER 1600/2600

EXAMPLES

The following examples are provided in order to demonstrate and further illustrate certain preferred embodiments and aspects of the present invention and are not to be construed as 5 limiting the scope thereof.

EXAMPLE 1

Inhibition of luciferase gene expression by siRNA in liver cells *in vivo*.

10 A. Preparation of siRNA

Single-stranded, gene-specific sense and antisense RNA oligomers with overhanging 3' deoxynucleotides are prepared and purified by PAGE. The two oligomers, 40 μ M each, are annealed in 250 μ l of buffer containing 50mM Tris-HCl, pH 8.0 and 100mM NaCl, by heating to 15 94 $^{\circ}$ C for 2 minutes, cooling to 90 $^{\circ}$ C for 1 minute, then cooling to 20 $^{\circ}$ C at a rate of 1 $^{\circ}$ C per minute. The resulting siRNA is stored at -20 $^{\circ}$ C prior to use.

The sense oligomer with identity to the luc+ gene has the sequence:


5'-rCrUrUrArCrGrCrUrGrArGrUrArCrUrUrCrGrATT-3' (SEQ ID NO: 1)
20 and corresponds to positions 155-173 of the luc+ reading frame. The letter "r" preceding a nucleotide indicates that nucleotide is a ribonucleotide.

The antisense oligomer with identity to the luc+ gene has the sequence:

5'-rUrCrGrArArGrUrArCrUrCrArGrCrGrUrArArGTT-3' (SEQ ID NO: 2)
25 and corresponds to positions 155-173 of the luc+ reading frame in the antisense direction. The letter "r" preceding a nucleotide indicates that nucleotide is a ribonucleotide.

The annealed oligomers containing luc+ coding sequence are referred to as siRNA-luc+.

30 The sense oligomer with identity to the ColE1 replication origin of bacterial plasmids has the sequence:



[REPLACEMENT SHEET]

5' -rGrCrGrArUrArArCrUrCrGrUrGrUrCrUrUrArArCTT-3' (SEQ ID NO: 3)

The letter "r" preceding a nucleotide indicates that nucleotide is a ribonucleotide.

The antisense oligomer with identity to the ColE1 origin of bacterial plasmids has the sequence:

5 5' -rGrUrArArGrArCrArCrGrUrArUrCrGrCTT-3' (SEQ ID NO: 4)

The letter "r" preceding a nucleotide indicates that nucleotide is a ribonucleotide.

The annealed oligomers containing ColE1 sequence are referred to as siRNA-ori.

10

B. Delivery of target DNA and siRNA to liver cells in mice

15 Plasmid pMIR48 (10 μ g), containing the luc+ coding region (Promega Corp.) and a chimeric intron downstream of the cytomegalovirus major immediate-early enhancer/promoter, is mixed with 0.5 or 5 μ g of siRNA-luc+ and diluted in 1-3 mls Ringer's solution (147mM NaCl, 4mM KCl, 1.13mM CaCl₂) and injected in the tail vein over 7-120 seconds.

20 C. Assay of Luc+ activity and assessment of siRNA induction of RNAi


One day after injection, the livers are harvested and homogenized in lysis buffer (0.1% Triton X-100, 0.1M K-phosphate, 1 mM DTT, pH 7.8). Insoluble material is cleared by centrifugation. 10 μ l of the cellular extract or extract diluted 10x is analyzed for luciferase activity using the Enhanced Luciferase Assay kit (Mirus).

25

Co-injection of 10 μ g of pMIR48 and 0.5 μ g of siRNA - luc+ results in 69% inhibition of Luc+ activity as compared to injection of 10g of pMIR48 alone. Co-injection of 5 μ g of siRNA- luc+ with 10 μ g of pMIR48 results in 93% inhibition of Luc+activity.

30 EXAMPLE 2

Inhibition of Luciferase expression by siRNA is gene specific in liver *in vivo*.



[REPLACEMENT SHEET]

and attempts to block both outflow and inflow of the blood to the leg. An efflux enhancer solution (e.g., 0.5 mg papaverine in 3 ml saline) is injected into the external iliac artery though a 25 - 27g needle, followed by the plasmid DNA and siRNA containing solution (in 10 ml saline) 1-10 minutes later. The solution is injected in approximately 10 seconds. The microvessel clips are 5 removed 2 minutes after the injection and bleeding controlled with pressure and gel foam. The abdominal muscles and skin are closed with 4-0 dexon suture. Each procedure takes approximately 15 minutes to perform.

Four days after injection, rats were sacrificed and the quadricep and gastrocnemius muscles were 10 harvested and homogenized as described in Example 1. Luc+ and Renilla Luc activities were assayed using the Dual Luciferase Reporter Assay System (Promega). Ratios of Luc+ to Renilla Luc were normalized to the siRNA-ori control. siRNA-Luc+ inhibited Luc+ expression in quadriceps and gastrocnemius by 85% and 92%, respectively, compared to the control siRNA-ori.

15

EXAMPLE 10

RNAi of SEAP reporter gene expression using siRNA in vivo.

Single-stranded, SEAP-specific sense and antisense RNA oligomers with overhanging 3' 20 deoxynucleotides are prepared and purified by PAGE. The two oligomers, 40 μ M each, are annealed in 250 μ l of buffer containing 50mM Tris-HCl, pH 8.0 and 100mM NaCl, by heating to 94 $^{\circ}$ C for 2 minutes, cooling to 90 $^{\circ}$ C for 1 minute, then cooling to 20 $^{\circ}$ C at a rate of 1 $^{\circ}$ C per minute. The resulting siRNA is stored at -20 $^{\circ}$ C prior to use.


25 The sense oligomer with identity to the SEAP reporter gene has the sequence:

5'-rArGrGrGrCrArArCrUrUrCrCrArGrArCrCrArUTT-3' (SEQ ID NO: 5)

and corresponds to positions 362-380 of the SEAP reading frame in the sense direction. The letter "r" preceding a nucleotide indicates that nucleotide is a ribonucleotide.

30 The antisense oligomer with identity to the SEAP reporter gene has the sequence:

5'-rArUrGrGrUrCrUrGrGrArArGrUrUrGrCrCrCrUTT-3' (SEQ ID NO: 6)



single-stranded, cytosolic alanine aminotransferase-specific sense and antisense RNA oligomers with overhanging 3' deoxynucleotides are prepared and purified by PAGE. The two oligomers, 40 μ M each, are annealed in 250 μ l of buffer containing 50mM Tris-HCl, pH 8.0 and 100mM NaCl, by heating to 94 $^{\circ}$ C for 2 minutes, cooling to 90 $^{\circ}$ C for 1 minute, then cooling to 20 $^{\circ}$ C at a 5 rate of 1 $^{\circ}$ C per minute. The resulting siRNA is stored at -20 $^{\circ}$ C prior to use.

The sense oligomer with identity to the endogenous mouse and rat gene encoding cytosolic alanine aminotransferase has the sequence:

5'-rCrArCrUrCrArGrUrCrUrArArGrGrGrCrUTT-3' (SEQ ID NO: 7)

10 and corresponds to positions 928-946 of the cytosolic alanine aminotransferase reading frame in the sense direction. The letter "r" preceding a nucleotide indicates that nucleotide is a ribonucleotide.

The sense oligomer with identity to the endogenous mouse and rat gene encoding cytosolic 15 alanine aminotransferase has the sequence:

5'-rArGrCrCrCrUrUrArGrArGrCrUrGrArGrUrGTT-3' (SEQ ID NO: 8)

and corresponds to positions 928-946 of the cytosolic alanine aminotransferase reading frame in the antisense direction. The letter "r" preceding a nucleotide indicates that nucleotide is a ribonucleotide.

20 The annealed oligomers containing cytosolic alanine aminotransferase coding sequence are referred to as siRNA-ALT

Mice are injected in the tail vein over 7-120 seconds with 40 μ g of siRNA-ALT diluted in 1-3 25 mls Ringer's solution (147mM NaCl, 4mM KCl, 1.13mM CaCl₂). Control mice were injected with Ringer's solution without siRNA. Two days after injection, the livers were harvested and homogenized in 0.25 M sucrose. ALT activity was assayed using the Sigma diagnostics INFINITY ALT reagent according to the manufacturers instructions. Total protein was determined using the BioRad Protein Assay. Mice injected with 40 μ g of siRNA-ALT had a 32% 30 average decrease in ALT specific activity compared to that of mice injected with Ringer's solution alone.